Loading...
XBRU
IBAB
Market cap390mUSD
Dec 05, Last price  
11.44EUR
1D
1.96%
1Q
-3.05%
Jan 2017
-72.53%
Name

Ion Beam Applications SA

Chart & Performance

D1W1MN
XBRU:IBAB chart
P/E
36.09
P/S
0.67
EPS
0.32
Div Yield, %
2.97%
Shrs. gr., 5y
0.53%
Rev. gr., 5y
12.01%
Revenues
498m
+16.21%
136,099,000170,257,000213,849,000332,607,000332,607,000387,591,000237,694,000221,106,000212,512,000220,577,000270,357,000328,774,000236,485,000257,406,999282,552,000311,955,000312,964,000361,270,000428,717,000498,200,000
Net income
9m
P
3,048,00030,007,00013,846,0005,329,0005,329,0006,643,000-84,128,000-5,800,000-4,098,00024,294,00061,189,00024,440,000-41,658,000-4,401,0007,610,00031,921,0003,879,0006,057,000-9,110,0009,300,000
CFO
-10m
L-49.42%
901,00013,652,00018,034,00011,916,00011,916,00031,412,00038,268,000-30,736,0006,763,00014,969,00045,394,000-17,018,000-44,641,000-18,521,00045,893,00098,254,00085,010,00020,897,000-19,769,000-10,000,000
Dividend
Jun 27, 20240.17 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
IPO date
Jun 13, 1998
Employees
2,000
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT